- Home
- NRO vs CHRS Comparison
NRO vs CHRS Comparison
Compare NRO & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRO
- CHRS
- Stock Information
- Founded
- NRO 2003
- CHRS 2010
- Country
- NRO United States
- CHRS United States
- Employees
- NRO N/A
- CHRS N/A
- Industry
- NRO Finance/Investors Services
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NRO Finance
- CHRS Health Care
- Exchange
- NRO Nasdaq
- CHRS Nasdaq
- Market Cap
- NRO 187.8M
- CHRS 191.3M
- IPO Year
- NRO N/A
- CHRS 2014
- Fundamental
- Price
- NRO $3.59
- CHRS $1.39
- Analyst Decision
- NRO
- CHRS Strong Buy
- Analyst Count
- NRO 0
- CHRS 4
- Target Price
- NRO N/A
- CHRS $5.38
- AVG Volume (30 Days)
- NRO 239.4K
- CHRS 2.0M
- Earning Date
- NRO 01-01-0001
- CHRS 03-12-2025
- Dividend Yield
- NRO 11.41%
- CHRS N/A
- EPS Growth
- NRO N/A
- CHRS N/A
- EPS
- NRO N/A
- CHRS N/A
- Revenue
- NRO N/A
- CHRS $304,340,000.00
- Revenue This Year
- NRO N/A
- CHRS $2.47
- Revenue Next Year
- NRO N/A
- CHRS N/A
- P/E Ratio
- NRO N/A
- CHRS N/A
- Revenue Growth
- NRO N/A
- CHRS 44.19
- 52 Week Low
- NRO $2.51
- CHRS $0.66
- 52 Week High
- NRO $3.45
- CHRS $2.97
- Technical
- Relative Strength Index (RSI)
- NRO 50.96
- CHRS 45.86
- Support Level
- NRO $3.45
- CHRS $1.38
- Resistance Level
- NRO $3.64
- CHRS $1.60
- Average True Range (ATR)
- NRO 0.08
- CHRS 0.13
- MACD
- NRO 0.02
- CHRS -0.03
- Stochastic Oscillator
- NRO 76.00
- CHRS 9.52
About NRO Neuberger Berman Real Estate Securities Income Fund Inc.
NEUBERGER BERMAN REAL ESTATE SECURITIES INCOME FUND INC is a closed-end management investment company that invests mainly in securities issued by real estate companies, including real estate investment trusts (REITs). Its primary objective is to gain high current income with capital appreciation being the second. The fund invests in sectors, such as apartments, Data Centers, Infrastructure REITs, Manufactured Homes, Office, Regional Malls and others.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.